|
Perez-Garcia JM, Llombart-Cussac A, G Cortes M, Curigliano G, Lopez-Miranda E, Alonso JL, Bermejo B, Calvo L, Caranana V, de la Cruz Sanchez S, M Vazquez R, Prat A, R Borrego M, Sampayo-Cordero M, Segui-Palmer MA, Soberino J, Malfettone A, Schmid P, Cortes J. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. Eur J Cancer. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. PubMed PMID: 33794440.
AÑO: 2021; IF: 10.002
|
|
Cascales Campos PA, Gonzalez-Gil A, Gomez-Ruiz AJ, Gil-Gomez E, Alconchel-Gago F, Navarro-Barrios A, Martinez-Garcia J, Alonso-Romero JL, Nieto A, Barcelo-Valcarcel F, Gil-Martinez J. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies. Hernia. 2020 Apr;24(2):257-263. doi: 10.1007/s10029-019-01962-4. Epub 2019 May 8. PubMed PMID: 31069579.
AÑO: 2020; IF: 2.92
|
|
Martinez-Garcia, J; Boix, AP; Henarejos, PS; Lucas, MDJ; Saura, AS; Luengo, M; Vicente, RC; Ortiz, MJM; Balsalobre, J; Barrio, PDLMD; Garre, EG; Garcia, E; Marin, G; Torralba, EG; de la Pena, FA; Collado, D; Lopez, A; Quiros, T; Sanchez, DA; Romero, JLA. Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study. ANNALS OF ONCOLOGY. 2020; 31:S358-S358. 10.1016/j.annonc.2020.08.393
AÑO: 2020; IF: 32.976
|
|
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz JA, Torres R, de la Haba J, Garcia-Martinez E, Gomez HL, Llombart A, Bofill JS, Baena-Canada JM, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernandez I, Rodriguez-Lescure A, Cardenas J, Vinholes J, Martinez de Duenas E, Godes MJ, Segui MA, Anton A, Lopez-Alvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martin M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. Epub 2019 Dec 5. Erratum In: J Clin Oncol. 2020 Mar 10;38(8):847. PubMed PMID: 31804894; PubMed Central PMCID: PMC6968797.
AÑO: 2020; IF: 44.544
|
|
Alvarez-Lopez, I; Gonzalez, E; Manso, LM; Alonso, JL; Cruz-Hernandez, JJ; Ballerini, VC; Gallegos, I; Varela, MQ; Illaramendi, JJ; Vicente, E; Garcia, AIB; de la Pena, FA; Perello, A; Vidal, J; Cussac, AL. Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel. ANNALS OF ONCOLOGY. 2020; 31:S29-S29. 10.1016/j.annonc.2020.03.173
AÑO: 2020; IF: 32.976
|